Aptevo Therapeutics (NASDAQ:APVO) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Aptevo Therapeutics (NASDAQ:APVO) from a hold rating to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Aptevo Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Aptevo Therapeutics Trading Down 1.5%

NASDAQ:APVO opened at $4.49 on Friday. The company has a market capitalization of $4.49 million, a P/E ratio of 0.00 and a beta of 1.43. Aptevo Therapeutics has a 12 month low of $3.95 and a 12 month high of $1,299.60. The business’s 50-day moving average is $6.91 and its 200 day moving average is $17.52.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. Institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.